Niacin, N-3 Fatty Acids and Insulin Resistance

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

August 31, 2008

Study Completion Date

December 31, 2008

Conditions

Metabolic SyndromeHypertriglyceridemia

Interventions

DRUG

omega-3 acid ethyl esters

4 q qd

DRUG

extended release niacin

2 g qpm

DRUG

placebo

omacor placebo plus niaspan placebo

DRUG

omega-3 acid ethyl esters

4 g qd

DRUG

combined treatment

omega-3 acid ethyl esters 4 g qd and extended release niacin, titrate up to 2 g Qpm

Trial Locations (1)

Sanford Clinic Clinical Research Services, Sioux Falls

All Listed Sponsors

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

University of South Dakota

OTHER

NCT00286234 - Niacin, N-3 Fatty Acids and Insulin Resistance | Biotech Hunter | Biotech Hunter